Last reviewed · How we verify
small cell lung cancer sclc
Approved treatments
Clinical guidelines
- FDA label — 1L
TECENTRIQ is indicated in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). - FDA label — maintenance
TECENTRIQ is indicated in combination with lurbinectedin for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- small cell lung cancer sclc patent landscape — cliff calendar, originator estates, attackable patents
- small cell lung cancer sclc treatment landscape brief
- small cell lung cancer sclc treatment updates RSS
Frequently asked questions about small cell lung cancer sclc
What are the treatment guidelines for small cell lung cancer sclc?
FDA label publishes guidelines for small cell lung cancer sclc. 2 guideline references tracked.
Related
- Treatment landscape: small cell lung cancer sclc patent cliff · small cell lung cancer sclc CI report
- All diseases: Browse the disease index · Disease landscape hub